At a glance
- Originator Alcon
- Class Antiglaucomas
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 18 Jul 2001 No-Development-Reported for Glaucoma in USA (Ophthalmic)
- 19 Aug 1998 Preclinical development for Glaucoma in USA (Ophthalmic)